Market Reports

Making a difference in pharma contract manufacturing

Making a difference in pharma contract manufacturing

With a plant near Basel, Switzerland, and a heritage of more than 40 years, contract service provider Legacy Pharmaceuticals understands the value of flexibility and experience when producing parenteral and semisolid drugs. Dr Kevin Robinson spoke to Mike Danzi, Chief Executive Officer, to find out more
Continuously driving pharmaceutical manufacturing efficiencies

Continuously driving pharmaceutical manufacturing efficiencies

Continuous manufacturing has long been accepted by a host of manufacturing industries from food and beverage to oil and gas, where it ensures the delivery of a consistent and continuous quality of product
Health experts reveal 10 most important medicines in NHS history

Health experts reveal 10 most important medicines in NHS history

Antipsychotics, breast cancer drug, oral contraceptives and MMR vaccine make the top 10
Brexit trade bill: Not yet

Brexit trade bill: Not yet

The UK has decided it will continue to be involved with the European Medicines Agency (EMA) after Brexit. Paul Brooks, Executive Director at the Regulatory Affairs Professionals Society (RAPS) asks what does this mean for the pharmaceutical industry and patients after 2020?
Maintenance across borders

Maintenance across borders

Here, Dave Friar, International Operations Director at Boulting, international engineering solutions provider, considers what you should do when preparing to hand over maintenance control on an overseas project
Treating chronic wounds with live biotherapeutics

Treating chronic wounds with live biotherapeutics

Angharad Baldwin talks to Evelina Vågesjö, CEO, and Peter Frank, Drug Development Manager, of Swedish biologics company, Ilya Pharma, about using live bacteria to treat chronic wounds
Isolator sterility put to the test

Isolator sterility put to the test

Sterility testing must be carried out under strict aseptic conditions. Stacey Orley, Wickham Laboratories, describes the process to ensure products and devices are contaminant-free
A new way of buying and selling APIs, additives, vitamins and excipients

A new way of buying and selling APIs, additives, vitamins and excipients

Swiss Kemiex and Atradius credit insurance launch unique commodity trading platform for the pharmaceutical and nutritional ingredients
The nanozyme that uses light to kill bacteria

The nanozyme that uses light to kill bacteria

Scientists at the RMIT University in Australia have created a nanozyme with antimicrobial properties with huge potential applications. Angharad Baldwin interviews Professor Vipul Bansal, lead researcher, to find out more
Six months and counting

Six months and counting

With 6 months to go until the DSCSA serialisation enforcement deadline kicks in, <i>Manufacturing Chemist</i> caught up with some leading lights in the industry to find out how companies were shaping up ahead of November to mark the occasion
Invisible benefits

Invisible benefits

SCHOTT enhances its iQ platform with the introduction of the new syriQ BioPure glass syringe for sensitive drugs
Accelerating drug discovery

Accelerating drug discovery

Angharad Baldwin of <i>Manufacturing Chemist</i> speaks to Dr Trevor Perrior, CSO of Domainex, about the development of a new GPCR drug discovery technology
The final countdown: CDMO focus areas before Feb 2019

The final countdown: CDMO focus areas before Feb 2019

Staffan Widengren will be presenting at <a href='https://www.tracelink.com/futurelink'>FutureLink Munich</a> on the <i>Final countdown: focus areas for a CDMO before February 2019</i>
How to boost the conversion rate of your e-commerce website in the manufacturing industry

How to boost the conversion rate of your e-commerce website in the manufacturing industry

Fifty three per cent of businesses spend less than 5% of their total marketing budget on boosting their conversion rates, and 35% of businesses have a conversion rate of less than 1%
Advances in medical technology

Advances in medical technology

Overhauling operating models to create digital value
Tailor-made molecules for the drugs of tomorrow

Tailor-made molecules for the drugs of tomorrow

Getting a drug to market is no easy feat, especially with tight regulations to comply with and the plethora of products that are already available. This is why a service that streamlines the discovery process and leads to improved outcomes during clinical trials for drug candidates is likely to be very desirable

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain
  2. A grandmaster’s approach to successful tableting Tableting is a fundamental unit operation in the production of pharmaceutical oral solid dosage forms. Despite its long history of use and the development of innovations such as extended dwell times, unique technologies that independently and simultaneously measure and control both tablet weight and hardness, and a weight control system that provides increased sensitivity at lower forces, production problems still occur. Here, Dr Harald Stahl, Group Director, Application and Strategy Management, GEA, provides some troubleshooting tips from an unlikely source: the chess board
  3. The modularisation of chemical API synthesis The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers
  4. Leaders of transformation Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development
  5. Is the production of biologic drugs ready for an overhaul? Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all